segigratinib

Segigratinib (also known as 3D185) is an orally bioavailable small molecule inhibitor that selectively targets fibroblast growth factor receptors FGFR1, FGFR2, and FGFR3, as well as the colony stimulating factor 1 receptor (CSF-1R). It exhibits potent antitumor activity by inhibiting both tumor cell proliferation driven by aberrant FGFR signaling and modulating the tumor microenvironment through CSF-1R inhibition. This dual mechanism allows it to suppress tumor growth directly and reduce immunosuppression mediated by macrophages. Segigratinib is being developed primarily for advanced solid tumors with particular focus on cancers characterized by aberrant FGFR signaling or abundant macrophage infiltration. The drug was developed by 3D Medicines and has received orphan drug designation from the FDA for biliary tract cancer, gastric cancer, and gastro-esophageal junction cancer. Clinical trials have reached Phase 2 in cholangiocarcinoma and Phase 1 in other advanced solid tumors[4][5][6][7].

Other names

FGFR/CSF-1R inhibitor 3D185